Brokerages Set Kura Oncology, Inc. (NASDAQ:KURA) Target Price at $29.86

Kura Oncology, Inc. (NASDAQ:KURA) has received an average rating of “Buy” from the ten research firms that are currently covering the company, Marketbeat Ratings reports. One analyst has rated the stock with a hold recommendation, eight have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokerages that have issued ratings on the stock in the last year is $29.86.

KURA has been the subject of a number of recent research reports. StockNews.com downgraded shares of Kura Oncology from a “hold” rating to a “sell” rating in a research note on Wednesday, November 20th. Lifesci Capital upgraded shares of Kura Oncology to a “strong-buy” rating in a research report on Tuesday, October 22nd. Bank of America reduced their price target on Kura Oncology from $36.00 to $29.00 and set a “buy” rating on the stock in a research report on Friday, November 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Kura Oncology in a report on Monday, December 9th. Finally, TD Cowen restated a “buy” rating on shares of Kura Oncology in a report on Thursday, November 21st.

Hedge Funds Weigh In On Kura Oncology

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of Kura Oncology in the third quarter valued at approximately $25,000. Point72 DIFC Ltd acquired a new stake in Kura Oncology in the 3rd quarter valued at $146,000. Quarry LP bought a new stake in Kura Oncology during the 2nd quarter worth about $196,000. Erste Asset Management GmbH acquired a new position in shares of Kura Oncology during the 3rd quarter worth about $215,000. Finally, Bellevue Group AG grew its holdings in shares of Kura Oncology by 36.0% in the 3rd quarter. Bellevue Group AG now owns 13,600 shares of the company’s stock valued at $266,000 after acquiring an additional 3,600 shares in the last quarter.

Kura Oncology Trading Up 2.4 %

Shares of KURA opened at $8.71 on Monday. The stock’s fifty day simple moving average is $12.83 and its 200-day simple moving average is $17.43. The company has a quick ratio of 11.47, a current ratio of 11.47 and a debt-to-equity ratio of 0.02. The firm has a market capitalization of $677.32 million, a PE ratio of -3.69 and a beta of 0.75. Kura Oncology has a 12-month low of $8.42 and a 12-month high of $24.17.

Kura Oncology Company Profile

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company’s pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.